| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/03/2006 | US6982272 E.g., 4-acetylamino-N-(1-((4-cyano-1-methylpiperidin-4-yl-carbamoyl)-2 -(cyclohexylethyl)benzamide; Alzheimer's, auto-immune and Crohn's diseases; atherosclerosis; antiarthritic agents; osteoporosis; atherosclerosis |
| 01/03/2006 | US6982270 1-Phenyl-2-oxo-3,4-dihydro-6-phenylaminoquinazoline for example; cytokine suppressive anti-inflammatory drugs; combination therapy |
| 01/03/2006 | US6982267 For therapy of metabolic and eating disorders such as obesity and hyperphagia, and therapy of diabetes |
| 01/03/2006 | US6982266 N-(4-indol-5-yloxyphenyl){4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}carboxamide for example; antiproliferative agents which inhibit phosphorylation of kinases such as tyrosine kinase; cancer, arteriosclerosis |
| 01/03/2006 | US6982263 Peptidyl carbamates; treatments for osteoporosis and autoimmune diseases |
| 01/03/2006 | US6982259 N-heterocyclic derivatives as NOS inhibitors |
| 01/03/2006 | US6982253 Liquid formulation of decitabine and use of the same |
| 01/03/2006 | US6982248 Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
| 01/03/2006 | US6982157 Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methylsulfonyl)amino] pyrimidin-5-yl] (3r,5s) -3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3A4 |
| 01/03/2006 | CA2359476C Hypolipidemic and antioxidant morpholine derivatives |
| 01/03/2006 | CA2343236C 4,4-biarylpiperidine derivatives |
| 01/03/2006 | CA2329005C Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 01/03/2006 | CA2264901C Association of no syntase inhibitors with trappers of oxygen reactive forms |
| 01/03/2006 | CA2162586C Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
| 12/29/2005 | WO2005123767A1 Peptide-based compounds |
| 12/29/2005 | WO2005123748A1 Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias |
| 12/29/2005 | WO2005123747A1 Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias |
| 12/29/2005 | WO2005123735A1 Process for producing evodiamine-containing composition |
| 12/29/2005 | WO2005123725A1 Novel compound having lipase inhibitory activity |
| 12/29/2005 | WO2005123721A2 Amorphous and polymorphic forms of candesartan cilexetil |
| 12/29/2005 | WO2005123720A1 Fine particles of the angiotensin ii antagonist candesartan cilexetil and process for production thereof |
| 12/29/2005 | WO2005123718A2 Benzimidazolone carboxylic acid derivatives |
| 12/29/2005 | WO2005123702A1 Neutral endopeptidase inhibitor polymorph |
| 12/29/2005 | WO2005123687A1 Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicaments |
| 12/29/2005 | WO2005123659A1 Method of synthesising (1s)-4,5-dimethoxy-1- (methylaminomethyl)-benzocyclobutane and the addition salts thereof, and use of same for the synthesis of ivabradine and the pharmaceutically-acceptable addition salts thereof |
| 12/29/2005 | WO2005123651A1 L-2-(α-HYDROXYPENTYL)BENZOATES, THE PREPARATION AND THE USE THEREOF |
| 12/29/2005 | WO2005123128A2 Methods for treating conditions associated with masp-2 dependent complement activation |
| 12/29/2005 | WO2003033671A3 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 12/29/2005 | WO2003012122A3 Crystallized structure of type iv collagen nc1 domain hexamer |
| 12/29/2005 | WO2002099040A3 Igs as modifiers of the p53 pathway and methods of use |
| 12/29/2005 | US20050289660 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 12/29/2005 | US20050289658 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 12/29/2005 | US20050288501 Reducing a 2-(protected amino)-3-(piperazin-1-yl, N-morpholinyl, or N-thiomorpholinyl) propanoate, deprotecting the amine, and reacting with t-butylisothiocyanate |
| 12/29/2005 | US20050288487 Human mast cell-expressed membrane proteins |
| 12/29/2005 | US20050288376 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides |
| 12/29/2005 | US20050288370 Polymorphic forms are suitable for use as active substances of pharmaceutical dosage forms for reduction of serum cholesterol levels in the bloodstream |
| 12/29/2005 | US20050288368 Compositions and methods for treating and preventing necrosis |
| 12/29/2005 | US20050288366 Administering N-(4-carboxybutyl)-N-(p-carboxybenzyl)-benzyl- or phenethyl-amine derivatives: 4-({(4-Carboxybutyl)[3-(4-cyclohexylphenoxy)benzyl]amino}methyl)-benzoic acid; stimulate soluble guanylate cyclase also via a novel mechanism of action which takes place without involvement of the heme group |
| 12/29/2005 | US20050288359 Agents and methods for the treatment of disorders associated with oxidative stress |
| 12/29/2005 | US20050288357 e.g. 4-(2-{2-[4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid; antiinflammatory, hypotensive, antiulcer agent |
| 12/29/2005 | US20050288356 Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics |
| 12/29/2005 | US20050288340 Substituted heteroaryl- and phenylsulfamoyl compounds |
| 12/29/2005 | US20050288337 Novel compounds |
| 12/29/2005 | US20050288335 Triamide-substituted heterobicyclic compounds |
| 12/29/2005 | US20050288325 Therapy for andropause using estrogen agonists/antagonists and testosterone |
| 12/29/2005 | US20050288311 2-(dipropylamino)-8-(4-thiomorpholinyl)pyrido[3,4-d]pyrimidin-4(3H)-one; kianses inhibitor; anticarcinlgenic, antidiabetic, antiinflammatory, hypotensive agent; nontoxic |
| 12/29/2005 | US20050288305 N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| 12/29/2005 | US20050288303 Cyclic protein tyrosine kinase inhibitors |
| 12/29/2005 | US20050288297 {4-[6-methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl]piperazinyl}-N-[4-(methylethoxy)phenyl]carboxamide; inhibits phosphorylation of platelet-derived growth factor receptor to hinder abnormal cell growth/wandering; cancer; arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis |
| 12/29/2005 | US20050288285 Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
| 12/29/2005 | US20050288263 2-(&agr;-Hydroxypently) benzoate and its preparation and use |
| 12/29/2005 | US20050288262 such as 3,10-Dibenzyloxyminocycline, used to treat bacterial infections and neoplasms, as well as blocking tetracycline efflux and modulation of gene expression |
| 12/29/2005 | US20050288254 Treating sepsis or septic shock by administering 1-stearoyl, 1-palmitoyl-, 1-myristoyl- lysophosphatidylcholine, or 1-oleoyllysophosphatidylcholine or sphingosylphosphorylcholine. |
| 12/29/2005 | US20050288232 As prodrug of enalaprilat, which is a medicine useful for preventing or treating circulatory diseases such as hypertension, cardiac diseases, nephritis, and apoplexy, patches; 1-[N-[(1S)-1-Carboxy-3-phenylpropyl]-L-alanyl]-L-proline 2-hydroxyethyl ester |
| 12/29/2005 | US20050287617 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 12/29/2005 | US20050287605 Caspase 3 inhibitors |
| 12/29/2005 | US20050287546 Novel proteases |
| 12/29/2005 | US20050287233 Compositions for preventing or ameliorating multiple risk factor syndromes |
| 12/29/2005 | US20050287195 Transdermal drug delivery systems |
| 12/29/2005 | US20050287144 For the modulation of signal activities controlled by NF-kappa B-inducing kinase (NIK); cancer , rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, asthma, cardiac infarct, Alzheimer's disease, or atherosclerosis |
| 12/29/2005 | DE19748040B4 Carbonsäurederivate, Verfahren zu ihrer Herstellung und pharmazeutische Präparate, die diese Verbindungen enthalten Carboxylic acid derivatives, processes for their preparation and pharmaceutical preparations containing these compounds |
| 12/29/2005 | CA2847677A1 Methods for treating conditions associated with masp-2 dependent complement activation |
| 12/29/2005 | CA2573144A1 Methods for treating conditions associated with masp-2 dependent complement activation |
| 12/29/2005 | CA2569308A1 Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias |
| 12/29/2005 | CA2568895A1 Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias |
| 12/29/2005 | CA2568601A1 Peptide-based compounds |
| 12/28/2005 | EP1609864A2 Use of neuronal apoptosis inhibitor protein (NAIP) |
| 12/28/2005 | EP1609861A1 Low-molecular weight peptides inhibiting ion channel activity |
| 12/28/2005 | EP1609856A2 Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof |
| 12/28/2005 | EP1609798A1 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
| 12/28/2005 | EP1609797A1 Compound having affinity with calcified tissue |
| 12/28/2005 | EP1609791A1 Preparation of [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[1-(3-Chloro-2-thienyl)methy]propy]amino]-3H-imidazo[4,5-b]pyridin-3-y]-N-ethyl-2,3-dihydroxycyclopentanecarboxamide |
| 12/28/2005 | EP1609790A2 Benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists |
| 12/28/2005 | EP1609788A1 Novel crystal of fluorobenzamide derivative |
| 12/28/2005 | EP1609504A1 T-type calcium channel blockers |
| 12/28/2005 | EP1609472A1 Therapeutic agent for hemorrhoidal disease |
| 12/28/2005 | EP1608659A1 Benzofuro-1,4-diazepin-2-one derivatives |
| 12/28/2005 | EP1608623A1 Metal ion chelators and therapeutic use thereof |
| 12/28/2005 | EP1608400A1 Elevation of adenosine level by cytokine-induced expression of cd73 |
| 12/28/2005 | EP1608396A2 Use of soluble cd14 for treatment of diseases |
| 12/28/2005 | EP1608389A1 Active ingredient combinations of plant oils containing omega-3 fatty acids and plant extracts containing isoprenoids and the use thereof |
| 12/28/2005 | EP1608379A1 Compositions for treating angina |
| 12/28/2005 | EP1608378A1 Prostaglandin compositions and their use for the treatment of vasospasm |
| 12/28/2005 | EP1608376A2 ACTIVATION SPECIFIC INHIBITORS OF NF-kB AND METHOD OF TREATING INFLAMMATORY PROCESSES IN CARDIO-VASCULAR DISEASES |
| 12/28/2005 | EP1608357A2 Treating or preventing hot flashes using prodrugs of gaba analogs |
| 12/28/2005 | EP1531831B1 Fosinopril formulation |
| 12/28/2005 | EP1527076B1 Dihydro-dibenzo[b,e]oxepine based selective estrogen receptor modulators, compositions and methods |
| 12/28/2005 | EP1497288B1 Novel ester hydroxy-substituted nitrogen heterocycles as antagonists of the muscarinic m3 receptor, methods for the production thereof, and use thereof as a medicament |
| 12/28/2005 | EP1470124B1 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES |
| 12/28/2005 | EP1435983B1 Concentrate comprising green tea, grape skin extract and grape seed extract, the production thereof and the use of the same |
| 12/28/2005 | EP1432415B1 Substituted 2,5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases |
| 12/28/2005 | EP1401502B1 Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer |
| 12/28/2005 | EP1382604B1 Quinoline derivative having azolyl group and quinazoline derivative |
| 12/28/2005 | EP1377593B1 2-amino-propanol derivatives |
| 12/28/2005 | EP1367060B1 Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
| 12/28/2005 | EP1299352B1 Compounds to treat alzheimer's disease |
| 12/28/2005 | EP1265867B1 Malonic acid derivates, processes for their preparation, their use as inhibitor of factor xa activity and pharmaceutical compositions containing them |
| 12/28/2005 | EP1254131B8 Extraction of flavonoids |
| 12/28/2005 | EP1251843B1 Compositions for delivery of a cortisol antagonist |
| 12/28/2005 | EP1246627B1 Polyanhydrides with biologically active degradation products |